Many patients today take GLP-1 receptor agonists or dual agonists, such as semaglutide or tirzepatide. At the same time, procedures keep coming up in everyday life, from dental surgery to a colonoscopy to a larger operation under general anesthesia. That quickly raises a very reasonable question: What applies to GLP-1 pre-surgery, and does the medication need to be paused before the procedure?
The medical background is understandable. GLP-1-based therapies can slow gastric emptying. With GLP-1 anesthesia or GLP-1 sedation, teams therefore look especially carefully at whether additional aspiration precautions may be needed. This refers to the risk of stomach contents entering the airways when protective reflexes are reduced. If you have already been noticing changes in hunger, fullness, and tolerability in everyday life, it also helps to look at GLP-1 in daily life, because that article clearly explains the typical gastrointestinal changes that can happen during treatment.
Why this matters in the perioperative setting
During sedation or anesthesia, protective reflexes are reduced. If food or fluid is still present in the stomach at that point, aspiration can occur in rare cases. That is exactly why GLP-1 surgery and other procedures involving reduced protective reflexes are assessed more carefully than everyday situations without sedation.
Clear context matters here. At present, the evidence points more clearly to a higher likelihood of retained stomach contents than to a clearly proven increase in actual aspiration events. In practice, that means the potential risk is taken seriously, but not every person on GLP-1 therapy is automatically considered high risk.
What do the current recommendations say?
There are many oversimplified statements circulating about GLP-1 pre-surgery. In reality, recommendations have evolved over the past few years. The earlier ASA recommendation from 2023 was more cautious and advised holding daily formulations on the day of the procedure and weekly formulations one week before the procedure. More recently, however, planning has become more individualized.
The current U.S. multisociety guidance emphasizes that most patients do not need to routinely stop GLP-1 medication before elective procedures. Instead, teams assess whether additional risk factors are present. A multidisciplinary consensus paper from the United Kingdom published in 2025 takes a similar approach. There as well, the focus is not on routine discontinuation, but on individualized risk assessment.
For you as a patient, that means there is no single rule that applies equally to every procedure and every person. What matters most are:
- the type of procedure
- the type of anesthesia or sedation
- current gastrointestinal symptoms
- the phase of treatment and any recent dose changes
- coexisting conditions and your individual risk profile
If you are being treated with Ozempic with semaglutide or GLP-1 therapy with Wegovy, the topic of semaglutide surgery anesthesia often comes up specifically. The same overall logic applies to dual agonists such as tirzepatide. That means Mounjaro with tirzepatide and Mounjaro surgery anesthesia are not a simple yes-or-no issue either, but a matter of individual planning.
Which procedures does this apply to?
In general, this affects all situations in which protective reflexes are reduced. That includes classic procedures under general anesthesia, but also many examinations performed with deep sedation or twilight sedation, such as endoscopic procedures including gastroscopy or colonoscopy. That is why GLP-1 sedation is discussed not only in anesthesiology, but also in gastroenterology.
For smaller procedures without sedation, or without any meaningful impairment of protective reflexes, the question is usually less critical. Even so, the medication should always be actively disclosed so the treating team can assess the situation correctly.
Who has a higher risk of a “full stomach”?
Not every person on GLP-1 therapy automatically has a high risk. In practice, clinicians pay closer attention when one or more of the following factors are also present:
- current gastrointestinal symptoms such as nausea, vomiting, marked fullness, or reflux
- the early phase of therapy or ongoing dose escalation
- high doses or a recent dose increase
- preexisting conditions that may affect gastric emptying
- prior issues with fasting, reflux, or aspiration risk
When these factors are present, teams more often choose a conservative strategy. For elective procedures, that may mean postponing the appointment, managing the patient as if they have a full stomach, or, in some centers, performing an additional assessment using gastric point-of-care ultrasound. If you want a clearer sense of how to interpret typical treatment-related symptoms, the article on digestive issues during injection therapy is also a helpful addition.
What you can do before the procedure
To help a GLP-1 surgery plan or examination be organized as safely as possible, clear information is what matters most in practice. These five steps are especially important:
1. Report the medication early
Tell the surgery, anesthesia, or endoscopy team early on that you are taking a GLP-1 medication or a dual agonist. Ideally, include the active ingredient, brand name, and whether it is a daily or weekly formulation.
2. Be open about symptoms
Clearly state whether you currently have nausea, vomiting, marked fullness, reflux, or constipation. These details are often more important for risk assessment than the simple fact that you take the medication. An additional point of reference is the article Managing side effects: warning signs checklist.
3. Follow fasting instructions exactly
The fasting instructions given by the team are a central safety measure. Follow the guidance closely for solid foods, clear liquids, and timing. If your risk is considered higher, stricter measures may also be recommended.
4. Clarify in advance whether the medication should be paused
The approach may vary depending on the procedure, the team, and your individual risk. That is why it should be discussed ahead of time whether the medication should be held, whether additional safety measures are needed, or whether therapy can continue unchanged.
5. Consider accompanying medications as well
If you also have diabetes, complex medication regimens, or other relevant conditions, planning should include how blood sugar and accompanying medications will be managed perioperatively. When several medications are involved, individualized coordination matters more than rigid rules.
Mini checklist: information that helps the team
Many misunderstandings arise not from “wrong” behavior, but from incomplete information. These details are especially helpful for the team:
- Which medication are you taking exactly?
- Is it a daily or weekly formulation?
- When was your last dose or injection?
- Are you currently in dose escalation, or has the dose been stable?
- Do you currently have nausea, vomiting, reflux, constipation, or marked fullness?
- Have you had previous problems with fasting, reflux, or aspiration?
Frequently asked questions about GLP-1, surgery, anesthesia, and sedation
Does this also apply to colonoscopy or gastroscopy?
Yes. Sedation is often used for endoscopic examinations as well, and protective reflexes may be reduced. That is why the issue is not relevant only for major surgery.
I have no symptoms. Do I still need to pause the medication?
That does not depend on the absence of symptoms alone. Some teams still follow older precautionary recommendations more closely, while others use a more individualized approach. What matters is that the medication is actively disclosed and that a safe plan is agreed on together.
What does “full stomach precautions” mean?
This refers to anesthetic safety measures used when a full stomach cannot be ruled out with confidence. The anesthesia or procedural team decides which measures are appropriate in the individual case.
Can the stomach be visualized before anesthesia?
Some hospitals use gastric point-of-care ultrasound to better estimate stomach contents. This is not standard everywhere, but it can be helpful in selected situations.
When can the medication be restarted after the procedure?
In practice, it is usually restarted once oral intake is safely possible and there are no signs of relevant complications such as postoperative ileus. The exact timing depends on the type of procedure and the clinical course.
Conclusion
GLP-1-based therapies can slow gastric emptying. That is why perioperative planning is especially important for procedures involving sedation or anesthesia. At the same time, one point is clearer today than at the start of the debate: not every person on GLP-1 therapy needs to routinely pause treatment. In most cases, the best strategy depends on the procedure, symptoms, treatment phase, and individual risk.
For patients, that mainly means stating early which medication is being taken, communicating current symptoms openly, and following fasting instructions exactly. If you want to discuss your specific situation in a structured way with a medical team, an eligibility assessment appointment may help align medication, the procedure, and safety planning.
Sources
- American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Agonists. 2023.
- American Society of Anesthesiologists. Most patients can continue diabetes, weight loss GLP-1 drugs before surgery. Multisociety clinical guidance. 2024.
- El-Boghdadly K, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement. Anaesthesia. 2025.
- Singh S, et al. Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review. J Clin Med. 2024.
- Goldenberg RM, et al. Perioperative and periprocedural management of GLP-1 receptor agonists. Narrative review. 2025.
- Li XY, et al. Perioperative management of patients on GLP-1 receptor agonists. Review. 2025.
- Robalino Gonzaga E, et al. Real-world impact of GLP-1 receptor agonists on retained gastric contents during elective EGD. 2024.
Disclaimer
This article is for informational purposes only and does not replace individualized medical advice. Decisions about what to do before a procedure should always be made together with a qualified physician and the responsible anesthesia or procedural team.